1 Dideoxyinosine (ddl) has recently been approved for the treatment of patients with HIV infection. As increasing numbers of such patients are pregnant, we wished to define the rate and mechanism(s) of ddl transfer by the placenta to the foetus. Using isolated single perfused human term placental cotyledons, the drug was shown to cross the placenta from mother to foetus at a rate of 25% that of a freely diffusible marker, antipyrine, and at about half the rate of zidovudine (AZT). The transfer of ddl was similar in both directions (maternal to foetal and the reverse), equal to that of L-glucose, a passively transported sugar, and was not inhibited by excess inosine or uric acid (structural analogues of ddl). ddl did not cross to the foetus against a concentration gradient. The transport process appeared to be passive and it was not altered by AZT. 2 ddl was not metabolized in the Krebs Ringer buffer/albumin perfusate, and placental homogenates converted only 4% of ddl to hypoxanthine over the 4 h incubation. However, when maternal term or cord blood was incubated with ddl for 3 h, 50% of the drug was converted to hypoxanthine in maternal blood and to hypoxanthine and uric acid in cord blood. 3 Thus, ddl metabolism in maternal blood should decrease its net transfer to the foetus in vivo. In the foetal circulation, ddl will be further metabolized by erythrocytes to hypoxanthine and possibly to uric acid. Hence, the fraction of administered ddl delivered to foetal tissues should be much lower than that of AZT.
Introduction
An increasing number of women of child-bearing age are exposed to human immunodeficiency virus (HIV) infection [1] . In 1989, some 6000 HIV-infected women delivered live children [2] and it has been estimated that 30% of these will have acquired HIV infection [2] . It is evident, therefore, that the use of anti-HIV drugs in this patient population will increase.
We [3] and others [4, 5] have previously characterized the transport of azidothymidine (AZT) by the term normal human placenta and have shown this process to be a passive one, consistent with the lipophilicity of the drug. In the present study we characterized the placental transfer of a newer therapeutic nucleoside, 2',3'-dideoxyinosine (ddl) [6] , using the isolated perfused single cotyledon technique [7] . Since ddl has been reported to be metabolized in human blood [8] we also assessed its stability on incubation with maternal and foetal blood, and placental homogenate. The possibility that concomitant placental transfer of AZT might affect transport of ddl was also investigated.
Methods

Placental pelfusion
The single, isolated, perfused'human placental cotyledon system utilizes normal fresh placenta at term, delivered vaginally or by Caesarian section. This method has been described extensively by others Correspondence: Dr Steven Schenker, 7703 Floyd Curl Drive, San Antonio, Texas 78284-7878, USA [7, 10] and often used by us [3, [11] [12] [13] . The placenta is perfused with heparinized Krebs-Ringer buffer immediately after delivery, and the foetal vessels supplying one cotyledon are cannulated with polyethylene catheters. After mounting in a perfusion chamber, the maternal compartment is perfused through needles placed in the intervillous space and the foetal compartment is perfused via the catheters. The system is oxygenated with room air delivered to each compartment, the pressure is maintained at 15-30 mm Hg, temperature kept at 370 C and the pH maintained at 7.4. The perfusate contains 2 g F-' albumin in Krebs-Ringer buffer and is delivered to the maternal side at a rate of 10 ml min-' and to the foetal side at a rate of 2-3 ml min-'. Antipyrine, a freely diffusible marker, (-)-glucose (transferred passively), or (-)-leucine (transported actively), were used as reference markers for various studies. Validation of the integrity of the system has been described earlier [11, 13] and depends on the absence of fluid shift between the separate compartments, expected passive or active transport of appropriate agents, and lack of transfer of large water-soluble agents (i.e. inulin) implying an absence of non-specific leaks. The first two of these criteria were reaffirmed in the present studies. The study was approved by the Institutional Review Board.
Three types of perfusions were carried out. In one series of experiments (open/open), ddl was infused over 90 min at a constant rate into the maternal (or foetal) compartment and its concentration was measured in the opposite effluent at nine 10 min intervals. The clearance of ddl, calculated as described earlier [11] [12] [13] was compared with that of antipyrine or (-)-glucose measured at the same time.
The concentrations of ddI used were 3 and 30 gM (7 jig ml-'), that of antipyrine was 1.06 mM (200 jig ml-'), and that of (-)-glucose was 80 nM. A concentration of 3 jM ddl is in the range of plasma drug concentrations seen in patients treated with ddl [14] . In another set of studies, ddl (30 jM) was placed in the maternal or foetal compartment and the maternal and foetal perfusions were recirculated over 4 h (closed system). Antipyrine (100 jig ml-') was added to the same compartment as ddl and the rates of transfer of the two compounds were compared over the linear portion of their transfer and expressed as a ddl/antipyrine transfer ratio. Both compounds were usually asssayed by scintillation spectrometry, although in some instances (when other labeled substances were used) antipyrine was measured spectrophotometrically [15] . In some studies, inosine (600 jM) and uric acid (833 jM (140 jg ml-')) (both structural analogues of ddl), or AZT (3 jM) (a concentration observed clinically [3] ) were also added initially to the maternal reservoir. The effects of these compounds on ddl transfer were then determined. The presence of ddl metabolites in the perfusion fluids at various times and in the perfused lobule at the end of the study (4 h) was determined by comparison of isotopic and h.p.l.c. peaks in the extract, as described below. Use of scintillation spectrometry to assay ddl is only fully valid if lack of metabolism of the parent drug is established. The presence of a single isotopic peak, with an identical retention time to that of pure ddl by h.p.l.c., would imply lack of significant metabolism of ddl.
In the third group of studies, ddl (30 jM) was infused at a constant rate into the maternal compartment (open system) and the same concentration of the drug was placed in the foetal recirculating system. Transfer into the foetal system and accumulation of the drug in that compartment with a foetal/maternal concentration greater than 1.0 would imply transport against a concentration gradient. Leucine, known to be actively transferred against such a gradient, served as a positive control.
Assay of metabolites
Blood Maternal blood samples were taken by venepuncture into heparinized tubes from normal term pregnant women on admission to the University Hospital, San Antonio, Texas. Blood samples were collected from the cord of term placentas (foetal samples) upon delivery. The blood samples were preincubated at 370 C for 10 min. To 1 ml of heparinized whole blood was added ['4C]-ddl and this was incubated for 0.5, 1, 2 and 3 h at 370 C. At the end of the incubation, 2 ml of cold methanol was added with vortexing and the mixture was centrifuged at 3000 g for 10 min. The supernatant was decanted and evaporated to dryness under nitrogen. The samples were reconstituted in 0.5 ml double-distilled water, filtered and concentrated with a Centricon® 10 micro-concentrator by centrifugation (5000 g for 60 min; Sorvall Superspeed RC2-B Automatic Refrigerated Centrifuge). much slower than that of antipyrine and similar to that of (-)-glucose. Moreover, as shown in Table 1 , ddl transfer in the opposite direction (foetal to maternal) was similar. As shown by the data in Table 2 from the closed (recirculation) studies, the mean maternal to foetal ddl/antipyrine transfer ratio at 30 min (the linear portion of antipyrine transfer) (see Figure 1) There was no inhibition of the clearance of ddl in the maternal to foetal direction on addition of 600 gM inosine (Table 1) . Similarly, this 20-fold inosine excess did not alter the maternal to foetal ddl/ antipyrine transfer ratio at 30 min in studies using the recirculating system (P > 0.05) ( Table 2 ). Comparison of the data at 45 and 60 min of transfer likewise indicated no statistically significant differences. Uric acid, in 20-fold excess by weight, did not alter the ddl/antipyrine transfer ratio at 30 min ( Table 2) .
As shown in Figure 3 , ddl did not cross the placenta from the maternal to the foetal side against a concentration gradient, while the positive control, leucine did so.
As shown in Table 2 , there was no effect of 3 ,UM AZT on ddl transfer. No ddl metabolites were detected in either maternal or foetal perfusates up to 4 h. Moreover, almost all of the isotope found in the perfused lobules at the end of 4 h of recirculation was in the form of ddl. In the in vitro homogenate studies, only 3.7 ± 1.4% of the label could be accounted for in the form of a metabolite, most likely hypoxanthine, by h.p.l.c. retention time. By contrast, 75% of added [14C]-inosine was rapidly metabolized, consistent with the finding of others [17] . There was no degradation of inosine in boiled placental homogenate.
As shown in Figure 4 , hypoxanthine was readily generated from [14C]-ddl in maternal and cord blood.
Uric acid was also apparently produced in the latter system.
Discussion
The results show that ddl crosses the perfused human term placenta from mother to foetus at a rate of 25% that of antipyrine, a freely diffusible marker, and half that of AZT [3] . Others have reported similar rates of placental transfer of ddl at term [5, 9] . The transfer of ddl across the placenta appeared to be a passive process as indicated by 1) a clearance equivalent to that of (-)-glucose, a passively transferred marker, 2) equal transfer in both directions, 3) lack of inhibition of transfer by excess amounts of the structural analogues, inosine and uric acid, and 4) absence of transfer against a placental ddl concen- (Table 2 ) was calculated at 30 min, the linear portion of antipyrine appearance in the foetal perfusate. tration gradient. Similar conclusions were reached by others using the perfused human placenta [5, 9] , as well as near term chronically catheterized pregnant macaques [16] . The lower rate of ddl transfer relative to AZT may be explained by its greater polarity [9] .
Significant amounts of ddl metabolites were not detected in the present studies, either in the perfusions or with in Oitro placental incubates. This contrasts with the finding of Dancis et al. [9] , using a non-recirculating system, where substantial metabolism of ddl was detected within I h of perfusion. Recalculation of the transfer rate of ddl on the basis of such metabolism would lower it by about 50% [9] . This also contrasts with data published recently by another group which measured ddl by h.p.l.c. [55] .
We have no explanation for the differences between our findings with regard to metabolism of ddl and those of Dancis et al. [9] . In a recent report, a 20 min incubation of ddl with human placental homogenate also failed to reveal ddl metabolites [17] .
The conversion of ddl to hypoxanthine in blood ( Figure 4 Time (min) Figure 2 Mean (± s.e mean) maternal (-) and foetal (0) perfusate concentrations of ddl and antipyrine after administration of the drug into the foetal reservoir of the human isolated perfused placenta preparation perfused in a recirculation mode (n = 4 preparations). The ddl/antipyrine transfer ratio (Table 2 ) was calculated at 30 min, the linear portion of antipyrine appearance in the foetal perfusate. side phosphorylase and that to uric acid by xanthine oxidase [8] . This is consistent with detection of metabolites with use of [14C]-ddl labeled in the purine ring. Thus, although in the blood-free in vitro placental preparation, ddl was essentially not metabolized, significant metabolism of ddl should occur in v7ixo in maternal blood thereby reducing net transfer of the drug to the foetus [9] . Moreover, in foetal blood, the half-life of ddl is likely to be decreased by metabolism of the drug. It seems, therefore, that based on significant metabolism of ddl in blood, the transfer of AZT to the foetus may be greater for a given dose than that of ddl. Indeed, foetal blood concentrations of ddl are only 18% of those in maternal blood [18] . Our data also indicate that AZT, given , , , , together with ddl, should not affect the placental 120 150 180 transfer of the latter. A similar conclusion was reached from studies in the near-term pregnant macaque [19] . Figure 3 Mean (± s.e mean) foetal to maternal perfusate concentration ratios of ddl (7) 
